TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35710394

Group type: EXPERIMENTAL
Intervention: Stepped care day patient approach
Number of subjects: 386

Group type: COMPARATOR
Intervention: Inpatient treatment as usual
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: Both groups (Stepped care day patient approach and Inpatient treatment as usual)
Number of subjects: 386
Study: 32469080

Group type: EXPERIMENTAL
Intervention: Uterus-preserving surgery (UPS)
Number of subjects: 185

Group type: COMPARATOR
Intervention: Non-Uterus-preserving surgery (non-UPS)
Number of subjects: 185
Study: 33721385

Group type: EXPERIMENTAL
Intervention: Microneedling radiofrequency (MRF)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Ablative fractional Er:YAG laser 2940 nm
Number of subjects: 21

Group type: COMPARATOR
Intervention: Both MRF and Er:YAG laser
Number of subjects: 21
Study: 32816177

Group type: EXPERIMENTAL
Intervention: PEEPINCREMENTAL
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: PEEPDECREMENTAL
Number of subjects: 60
Study: 33160946

Group type: EXPERIMENTAL
Intervention: Myval transcatheter heart valve (THV) series
Number of subjects: 768

Group type: COMPARATOR
Intervention: Contemporary transcatheter heart valves (SAPIEN THV and Evolut THV series)
Number of subjects: 768
Study: 33223005

Group type: EXPERIMENTAL
Intervention: 0.75 mg.kg‐1 flurbiprofen axetil (Group C)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: 1 mg.kg‐1 flurbiprofen axetil (Group D)
Number of subjects: 96

Group type: COMPARATOR
Intervention: 10 mL of Intralipid (Group A, control group)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: 0.5 mg.kg‐1 flurbiprofen axetil (Group B)
Number of subjects: 96
Study: 36346795

Group type: EXPERIMENTAL
Intervention: PACE labels on intervention items
Number of subjects: 19000

Group type: EXPERIMENTAL
Intervention: PACE labels on non-intervention items
Number of subjects: 19000

Group type: EXPERIMENTAL
Intervention: PACE labels on total energy purchased
Number of subjects: 19000
Study: 32141787

Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA 400 U injection in J-PURE (upper limb)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA 400 U injection in J-PLUS (lower limb)
Number of subjects: 22
Study: 35229691

Group type: EXPERIMENTAL
Intervention: Convalescent plasma added to conventional therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0.9% normal saline (saline) control
Number of subjects: 0
Study: 32241351

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) applied every 4 weeks for 12 weeks
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control (sham application)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT)
Number of subjects: 22
Study: 35849650

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 193

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 193
Study: 32621535

Group type: EXPERIMENTAL
Intervention: Deauville score (DS) 1 (n=34)
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Deauville score (DS) 2 (n=39)
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Deauville score (DS) 3 (n=46)
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Deauville score (DS) 4 (n=56)
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Deauville score (DS) 5 (n=14)
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: ∆SUVmax ≥66% (n=168)
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: ∆SUVmax <66% (n=21)
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Deauville score (DS) 1-5
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: ∆SUVmax ≥66%
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: ∆SUVmax <66%
Number of subjects: 189
Study: 34036828

Group type: EXPERIMENTAL
Intervention: Systematic visual oral examinations for screening
Number of subjects: 0

Group type: COMPARATOR
Intervention: Opportunistic screening in dental practices
Number of subjects: 0

Group type: COMPARATOR
Intervention: Use of primary health care workers for oral cancer screening
Number of subjects: 0
Study: 32470370

Group type: EXPERIMENTAL
Intervention: 50 mg Diclofenac Potassium (DFK)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 70
Study: 33877274

Group type: EXPERIMENTAL
Intervention: Poloxamer 188
Number of subjects: 388

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 388
Study: 33866827

Group type: EXPERIMENTAL
Intervention: Post-HRRP penalty phase (2013-2017)
Number of subjects: 6669313

Group type: COMPARATOR
Intervention: Pre-HRRP penalty phase (2010-2012)
Number of subjects: 6669313

Group type: EXPERIMENTAL
Intervention: 2010-2017 trend analysis
Number of subjects: 6669313
Study: 35853436

Group type: EXPERIMENTAL
Intervention: Tafamidis
Number of subjects: 441

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 441
Study: 33738466

Group type: EXPERIMENTAL
Intervention: Primary rhinoplasty
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Revision rhinoplasty
Number of subjects: 134

Group type: COMPARATOR
Intervention: Comparison of revision rhinoplasty to primary rhinoplasty
Number of subjects: 134
Study: 32551724

Group type: EXPERIMENTAL
Intervention: Dialogical Exposure Therapy (DET)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Both therapies (DET and CPT)
Number of subjects: 110
Study: 36089507

Group type: EXPERIMENTAL
Intervention: DASH diet based on plant proteins
Number of subjects: 90

Group type: COMPARATOR
Intervention: DASH diet based on animal proteins
Number of subjects: 90
Study: 36170543

Group type: EXPERIMENTAL
Intervention: Educational materials delivered with 'take‐home and cook‐with‐friends' meal kits
Number of subjects: 186

Group type: COMPARATOR
Intervention: Meal kits only (control group)
Number of subjects: 186
Study: 33126095

Group type: EXPERIMENTAL
Intervention: Anti-industry counter-advertising (CA)
Number of subjects: 1316

Group type: EXPERIMENTAL
Intervention: Anti-product counter-advertising (CA)
Number of subjects: 1316

Group type: EXPERIMENTAL
Intervention: Negative health effects counter-advertising (CA)
Number of subjects: 1316

Group type: COMPARATOR
Intervention: Control (neutral advertisement)
Number of subjects: 1316
Study: 33926539

Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RFA) followed by chemotherapy
Number of subjects: 228

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 228
Study: 33284852

Group type: EXPERIMENTAL
Intervention: Cooperative games
Number of subjects: 285
Study: 34460897

Group type: EXPERIMENTAL
Intervention: 12-week outpatient physical therapy program with progressive resistance training (PRT)
Number of subjects: 100

Group type: COMPARATOR
Intervention: 6-week outpatient physical therapy program with progressive resistance training (PRT)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Comparison between 12-week and 6-week groups
Number of subjects: 100
Study: 33452496

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Intravenous oxytocin
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 16
Study: 32532789

Group type: EXPERIMENTAL
Intervention: Nivolumab 3 mg/kg once every 2 weeks until disease progression or unacceptable toxicity
Number of subjects: 270
Study: 36113907

Group type: EXPERIMENTAL
Intervention: Sleep deprivation
Number of subjects: 52

Group type: COMPARATOR
Intervention: Normal sleep
Number of subjects: 52
Study: 33630677

Group type: EXPERIMENTAL
Intervention: Combined aerobic and resistance training (CT)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Aerobic training (AT)
Number of subjects: 55
Study: 32131366

Group type: EXPERIMENTAL
Intervention: Group A received a sachet containing 5 g CPs, 3.6 g calcium lactate (equivalent to 500 mg of elemental calcium) and 400 IU vitamin D3
Number of subjects: 51

Group type: COMPARATOR
Intervention: Group B received a chewable tablet containing 1.25 g calcium carbonate (equivalent to 500 mg of elemental calcium) and 400 IU vitamin D3 daily
Number of subjects: 51
Study: 33496967

Group type: EXPERIMENTAL
Intervention: Intra-operative dexmedetomidine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 32379687

Group type: EXPERIMENTAL
Intervention: Vitamin D for 12 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 0
Study: 36347107

Group type: EXPERIMENTAL
Intervention: GOT + IOT
Number of subjects: 102

Group type: COMPARATOR
Intervention: GOT alone
Number of subjects: 102
Study: 34286863

Group type: EXPERIMENTAL
Intervention: Self-care education programme (video-assisted teaching, tailored teaching at discharge, guide on self-care, telephonic calls and text messages for 6 months)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Standard care plus self-care guide
Number of subjects: 160
Study: 35213433

Group type: EXPERIMENTAL
Intervention: Indocyanine green group
Number of subjects: 64

Group type: COMPARATOR
Intervention: Nonindocyanine green group
Number of subjects: 64

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 64
Study: 36400573

Group type: EXPERIMENTAL
Intervention: Flipped classroom model
Number of subjects: 42

Group type: COMPARATOR
Intervention: Traditional lecture method (Control)
Number of subjects: 42
Study: 34337893

Group type: EXPERIMENTAL
Intervention: Normoxia (NX; room air; FIO2 0.21)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Hypoxia (HX; FIO2 0.148)
Number of subjects: 28
Study: 32764898

Group type: EXPERIMENTAL
Intervention: FNB (femoral nerve block) with 15 mL of 0.5% ropivacaine
Number of subjects: 46

Group type: COMPARATOR
Intervention: FICB (fascia iliaca compartment block) with 40 mL of 0.5% ropivacaine
Number of subjects: 46
Study: 32814922

Group type: EXPERIMENTAL
Intervention: Dispatcher-assisted cardiopulmonary resuscitation instructions
Number of subjects: 21
Study: 36385193

Group type: EXPERIMENTAL
Intervention: Vitamin D3 (3200 IU/d)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Calcifediol (HyD, 20 mcg/d)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 34448725

Group type: EXPERIMENTAL
Intervention: App intervention
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: App usage
Number of subjects: 54
Study: 32934291

Group type: EXPERIMENTAL
Intervention: Novel insecticide‐based intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Deltamethrin exposure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transcriptome analysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cyp6P3 expression
Number of subjects: 0
Study: 34742935

Group type: EXPERIMENTAL
Intervention: PCOS Kind Mind Program
Number of subjects: 0
Study: 33433351

Group type: EXPERIMENTAL
Intervention: Test formulation of perindopril tert-butylamine tablets (4 mg)
Number of subjects: 64
Study: 34263280

Group type: EXPERIMENTAL
Intervention: 50 mg of daidzein with 10 g soy protein
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: 50 mg of genistein with 10 g soy protein
Number of subjects: 165

Group type: COMPARATOR
Intervention: 0 mg of daidzein and genistein with 10 g soy protein (placebo group)
Number of subjects: 165
Study: 34949544

Group type: EXPERIMENTAL
Intervention: OCT-guided magnesium bioresorbable scaffold (MBRS) implantation
Number of subjects: 75

Group type: COMPARATOR
Intervention: Angiography-guided magnesium bioresorbable scaffold (MBRS) implantation
Number of subjects: 75
Study: 34604139

Group type: EXPERIMENTAL
Intervention: Nasotracheal intubation
Number of subjects: 70

Group type: COMPARATOR
Intervention: Orotracheal intubation
Number of subjects: 70
Study: 35247994

Group type: EXPERIMENTAL
Intervention: High intensity exercise intervention (supervised and group-based exercise training, primarily intermediate to high intensity interval training, three times per week for 6 weeks)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: High intensity exercise intervention
Number of subjects: 70

Group type: COMPARATOR
Intervention: Standard oncological treatments (checkpoint inhibitors, checkpoint inhibitors combined with chemotherapy or oncological surveillance)
Number of subjects: 70
Study: 32610246

Group type: COMPARATOR
Intervention: Efficient ICUs
Number of subjects: 13635

Group type: EXPERIMENTAL
Intervention: Active surveillance of ventilator-associated pneumonia
Number of subjects: 13635

Group type: EXPERIMENTAL
Intervention: Utilization of central venous catheters
Number of subjects: 13635
Study: 34951124

Group type: EXPERIMENTAL
Intervention: Hybrid Hyrax (HHG)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Hyrax (HG)
Number of subjects: 42
Study: 32342662

Group type: EXPERIMENTAL
Intervention: HAPA intervention with tailored text messages
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 36379661

Group type: EXPERIMENTAL
Intervention: My Life After Stroke (MLAS) programme
Number of subjects: 420

Group type: COMPARATOR
Intervention: Declined MLAS
Number of subjects: 420
Study: 32666354

Group type: EXPERIMENTAL
Intervention: Desvenlafaxine succinate monohydrate extended release tablets
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: In vitro dissolution tests using USP apparatus 1 at 75 rpm with HCl pH 1.2, acetate buffer solution pH 4.5, or phosphate buffer solution pH 6.8
Number of subjects: 0
Study: 34029230

Group type: EXPERIMENTAL
Intervention: Standardized postoperative anesthesia visits on day 1 and 3
Number of subjects: 5473

Group type: COMPARATOR
Intervention: Routine use of MEWS
Number of subjects: 5473

Group type: EXPERIMENTAL
Intervention: Standardized postoperative anesthesia visits
Number of subjects: 5473
Study: 34406788

Group type: EXPERIMENTAL
Intervention: Conidial suspension (1 × 10^6 conidia/ml) inoculation on three leaves of three plants
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Mycelial plugs (5 × 5 mm3) inoculation on three leaves of three plants
Number of subjects: 100

Group type: COMPARATOR
Intervention: Mock inoculations with sterile water and non-infested PDA plugs on three leaves each
Number of subjects: 100
Study: 32794449

Group type: EXPERIMENTAL
Intervention: Online imaginal exposure therapy for EDs (4 sessions over 4 weeks)
Number of subjects: 229
Study: 35358015

Group type: EXPERIMENTAL
Intervention: 4vHPV vaccine
Number of subjects: 368

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 368
Study: 33386202

Group type: EXPERIMENTAL
Intervention: Submental island flap reconstruction
Number of subjects: 60

Group type: COMPARATOR
Intervention: Maxillary obturator reconstruction
Number of subjects: 60
Study: 32358477

Group type: EXPERIMENTAL
Intervention: Fascia iliaca block (FIB)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Control group (no block)
Number of subjects: 97
Study: 35851045

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol 200/6 μg via turbuhaler
Number of subjects: 49

Group type: COMPARATOR
Intervention: Salbutamol 100 μg via MDI
Number of subjects: 49
Study: 32108027

Group type: EXPERIMENTAL
Intervention: High-density lipoprotein (HDL)
Number of subjects: 10686

Group type: EXPERIMENTAL
Intervention: Triglycerides (TG)
Number of subjects: 10686
Study: 35889801

Group type: EXPERIMENTAL
Intervention: Exercise and Fish Oil (EFO)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Exercise and Placebo (EP)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 34
Study: 32957817

Group type: EXPERIMENTAL
Intervention: Truncal ITA ligation
Number of subjects: 319

Group type: COMPARATOR
Intervention: Branch ITA ligation
Number of subjects: 319
Study: 36137682

Group type: EXPERIMENTAL
Intervention: Apixaban 5 mg twice daily
Number of subjects: 762

Group type: COMPARATOR
Intervention: Standard of care (vitamin K antagonists or antiplatelet therapy)
Number of subjects: 762

Group type: EXPERIMENTAL
Intervention: Apixaban vs antiplatelet therapy
Number of subjects: 762

Group type: EXPERIMENTAL
Intervention: Apixaban vs vitamin K antagonists
Number of subjects: 762

Group type: EXPERIMENTAL
Intervention: Subclinical valve thrombosis
Number of subjects: 762

Group type: COMPARATOR
Intervention: No subclinical valve thrombosis
Number of subjects: 762
Study: 34217889

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy-based pain coping skills training with optional opioid taper support (18 telephone sessions over 52 weeks)
Number of subjects: 215

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy-based pain coping skills training with optional opioid taper support
Number of subjects: 215
Study: 34842343

Group type: EXPERIMENTAL
Intervention: Omega 3 fatty acids 1000 mg/day for 6 months
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual doxorubicin protocol
Number of subjects: 60
Study: 34374980

Group type: EXPERIMENTAL
Intervention: Thoracolumbar interfascial plane (TLIP) block with ultrasound guidance
Number of subjects: 42

Group type: COMPARATOR
Intervention: Local anesthetic infiltration (bupivacaine) on the surgical incision line
Number of subjects: 42
Study: 34644414

Group type: EXPERIMENTAL
Intervention: Doxorubicin with dexrazoxane
Number of subjects: 1308

Group type: COMPARATOR
Intervention: Doxorubicin without dexrazoxane
Number of subjects: 1308

Group type: EXPERIMENTAL
Intervention: Dexrazoxane (P9754 patients)
Number of subjects: 1308

Group type: COMPARATOR
Intervention: CCSS osteosarcoma survivors (no dexrazoxane)
Number of subjects: 1308
Study: 33069121

Group type: EXPERIMENTAL
Intervention: Memantine (5 mg/day)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 155
Study: 35174649

Group type: EXPERIMENTAL
Intervention: semaglutide 0.5 mg
Number of subjects: 909

Group type: EXPERIMENTAL
Intervention: semaglutide 1.0 mg
Number of subjects: 909

Group type: COMPARATOR
Intervention: comparators (sitagliptin or OADs)
Number of subjects: 909
Study: 32757086

Group type: EXPERIMENTAL
Intervention: Closed loop stimulation (CLS)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Standard accelerometer (DDDR)
Number of subjects: 9
Study: 35921055

Group type: EXPERIMENTAL
Intervention: Team-guided ICBT
Number of subjects: 178

Group type: COMPARATOR
Intervention: Self-guided ICBT
Number of subjects: 178
Study: 32324065

Group type: EXPERIMENTAL
Intervention: Ertugliflozin 5 mg
Number of subjects: 1178

Group type: EXPERIMENTAL
Intervention: Ertugliflozin 15 mg
Number of subjects: 1178

Group type: COMPARATOR
Intervention: Glimepiride
Number of subjects: 1178

Group type: EXPERIMENTAL
Intervention: Ertugliflozin 5 mg/sitagliptin
Number of subjects: 1178

Group type: EXPERIMENTAL
Intervention: Ertugliflozin 15 mg/sitagliptin
Number of subjects: 1178

Group type: COMPARATOR
Intervention: Sitagliptin
Number of subjects: 1178

Group type: EXPERIMENTAL
Intervention: Ertugliflozin (as single agent or combined with sitagliptin)
Number of subjects: 1178

Group type: EXPERIMENTAL
Intervention: Ertugliflozin
Number of subjects: 1178
Study: 35568494

Group type: COMPARATOR
Intervention: COT (Conventional Occupational Therapy)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: COT+CCH (Conventional Occupational Therapy + Chinese Calligraphy Handwriting)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: COT+GRASP (Conventional Occupational Therapy + Graded Repetitive Arm Supplementary Program)
Number of subjects: 60
Study: 33345396

Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy (docetaxel or paclitaxel)
Number of subjects: 0
Study: 32794176

Group type: EXPERIMENTAL
Intervention: Transnasal Humidified Rapid‐Insufflation Ventilatory Exchange (THRIVE) with 100% oxygen at 70 l min−1 during apnoea
Number of subjects: 30

Group type: COMPARATOR
Intervention: Mechanical ventilation with intubation and normoventilation at FiO2 of 0.4
Number of subjects: 30
Study: 33057772

Group type: EXPERIMENTAL
Intervention: Combined Model consisting of 2 clinical factors, 2 tumor markers, 7 PET radiomics, and 3 CT radiomic parameters
Number of subjects: 315

Group type: COMPARATOR
Intervention: Clinical factors-tumor markers
Number of subjects: 315

Group type: COMPARATOR
Intervention: PET radiomics
Number of subjects: 315

Group type: COMPARATOR
Intervention: CT radiomics
Number of subjects: 315
Study: 35906655

Group type: EXPERIMENTAL
Intervention: Lactation-specific relaxation and visualisation intervention
Number of subjects: 132
Study: 32738099

Group type: EXPERIMENTAL
Intervention: Dinaciclib (6-12 mg/m2 i.v.) and MK-2206 (60-135 mg p.o.) weekly
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Dinaciclib (9 mg/m2) and MK-2206 (135 mg) at recommended dose
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Dinaciclib and MK-2206 combination
Number of subjects: 39
Study: 35144911

Group type: EXPERIMENTAL
Intervention: Drug trials in GP practices
Number of subjects: 87
Study: 36006207

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BoNT‐A) injection (50 U)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Saline injection (control)
Number of subjects: 57
Study: 32666576

Group type: EXPERIMENTAL
Intervention: Multi-professional medication review (MPMR) service
Number of subjects: 826

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 826
Study: 35132024

Group type: EXPERIMENTAL
Intervention: Gabapentin enacarbil 600 mg twice daily starting the day before surgery continuing for 3 days thereafter
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Gabapentin enacarbil
Number of subjects: 60
Study: 32389147

Group type: EXPERIMENTAL
Intervention: Dissociative seizures (DS) cohort
Number of subjects: 368
Study: 32361698

Group type: EXPERIMENTAL
Intervention: Combined aerobic and resistance exercise program during dialysis for 16 weeks
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 45
Study: 34591227

Group type: EXPERIMENTAL
Intervention: IRLA with heated lidocaine gel (20 mL 2% lidocaine gel at 40 ℃)
Number of subjects: 153

Group type: COMPARATOR
Intervention: IRLA with room temperature lidocaine gel (20 mL 2% lidocaine gel)
Number of subjects: 153

Group type: COMPARATOR
Intervention: No local anesthesia
Number of subjects: 153
Study: 35113456

Group type: EXPERIMENTAL
Intervention: 9-hour modified psychological first aid (PFA) training program
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 150
Study: 32265417

Group type: EXPERIMENTAL
Intervention: ANG-3777 (2 mg/kg, 3 once-daily IV infusions)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: ANG-3777
Number of subjects: 28